Considering that clonal evolution is frequent in lymphoma, most TP53 mutations detected in relapsed/refractory patients may be from emerging clones during treatment that contribute to tumor relapse, as reported by previous studies in other lymphomas (33, 34). The gene discussed is TP53; the disease is neoplasm.